About Lords Mark Biotech Private Limited
Data last updated: 06 March 2026
Lords Mark Biotech Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Lord's Mark Industries Limited. It specialises in diagnostic centers and pathology labs, a part of the broader healthcare sector. Incorporated on 10 November 2022.
Registered with ROC Mumbai under CIN U24290MH2022PTC393233.
Capital: an authorised share capital of ₹5 Cr and a paid-up capital of ₹5 Cr. It is led by directors Anurag Kar and Dharmendra Navin Sinha.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: B 101 Ridhi Sidhi Complex M.G Road Borivali East Mumbai, Maharashtra, India – 400066.
As per the financials filed for FY 2025, the company reported a revenue of ₹57.23 Cr, a growth of 57% compared to the previous year.
The company has a workforce of approximately 196 employees as per the latest available data. It operates as a subsidiary of Lord's Mark Industries Limited.
The company is associated with 2 brands - Lords Mark Biotech, Lord's Mark. As per MCA filings, the company has open charges of ₹16.3 Cr on record.
For more details, the company can be reached via its website lordsmark.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressB 101 Ridhi Sidhi Complex M.G Road Borivali East Mumbai, Maharashtra, India – 400066
-
IndustryHealthcare, Diagnostic Centers & Pathology Labs
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Lords Mark Biotech Private Limited
Lords Mark Biotech Private Limited operates two associated brands: Lords Mark Biotech and Lord's Mark. These brands represent Lords Mark Biotech Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Sells orthopedic braces and supports for back, neck, knee, ankle, and wrist pains. | lordsmarkbiotech.com | |
| Renewable energy products are manufactured by Lords Mark in India. | lordsmark.com |
Competitors & Alternatives of Lords Mark Biotech Private Limited
Brands and companies operating in the same space as Lords Mark Biotech Private Limited include Merck, Roivant Sciences, GE Healthcare and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Merck
|
Pharmaceutical products are manufactured and marketed worldwide. | Kenilworth, United Kingdom, United Kingdom | 1891 |
Roivant Sciences
|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | New York, United States, United States | 2014 |
GE Healthcare
|
Materials management solutions are provided for healthcare organizations. | Chicago, United States, United States | 1892 |
AbbVie
|
Biopharmaceutical research and drug development are conducted globally by AbbVie. | Chicago, United States, United States | 2012 |
Lilly
|
Traditional pharmaceutical medicines are developed for multiple health fields. | United States | 1876 |
Gilead
|
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | Foster City, United States, United States | 1987 |
Medtronic
|
Medical equipment for treating over 30 chronic diseases is developed. | Minneapolis, United States, United States | 1949 |
United Therapeutics
|
Treatments for chronic and life-threatening diseases are developed and commercialized. | Silver Spring, United States, United States | 1998 |
Roche
|
Pharmaceuticals and diagnostics kits are developed for various diseases. | Basel, Switzerland, Switzerland | 1896 |
Ascendis Pharma
|
Long-acting prodrug therapies are developed for endocrine and rare diseases. | Hellerup, Denmark, Denmark | 2007 |
Business Activity of Lords Mark Biotech Private Limited
Lords Mark Biotech Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Lords Mark Biotech Private Limited
Lords Mark Biotech Private Limited is audited by Omprakash Kedia & Co. for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Omprakash Kedia & Co. | blur-value | blur-value | blur-value |
Board of Directors of Lords Mark Biotech Private Limited
Lords Mark Biotech Private Limited is currently managed by 2 directors, with 2 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Anurag Kar
Also directs:
Lords Mark Organics India Private Limited, Devam Electric Vehicles Private Limited, Lords Green Energy Private Limited and 1 more
|
Additional Director | 17 Mar 2025 | 1 Years 3 Months | Current |
| Dharmendra Navin Sinha | Additional Director | 17 Mar 2025 | 1 Years 3 Months | Current |
Financials of Lords Mark Biotech Private Limited FY 2025 filings available
Lords Mark Biotech Private Limited reported revenue of ₹57.23 Cr (up 57% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Lords Mark Biotech Private Limited
As of FY 2023, Lords Mark Biotech Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Lords Mark Biotech Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Sep 2023 | Canara Bank | ₹3 Cr | Open |
| 23 Mar 2023 | Others | ₹13.3 Cr | Open |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Lords Mark Biotech Private Limited
View historical data on people associated with Lords Mark Biotech Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Lords Mark Biotech Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Lords Mark Biotech Private Limited
GSTIN & GST Filing Data of Lords Mark Biotech Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Lords Mark Biotech Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Lords Mark Biotech Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Lords Mark Biotech Private Limited
MSME Payment Delays by Lords Mark Biotech Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Lords Mark Biotech Private Limited
Subsidiaries & Group Companies of Lords Mark Biotech Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Lords Mark Biotech Private Limited with ownership details.
MCA Filings & Documents of Lords Mark Biotech Private Limited
MCA Filings & Documents of Lords Mark Biotech Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Lords Mark Biotech Private Limited
Recent News on Lords Mark Biotech Private Limited
Frequently Asked Questions about Lords Mark Biotech Private Limited
Lords Mark Biotech Private Limited is an active private limited company in the healthcare sector based in Mumbai, Maharashtra, India. It was incorporated on 10 November 2022 (4+ years old) and is registered under CIN U24290MH2022PTC393233. The company has 196 employees.
Lords Mark Biotech Private Limited reported revenue of ₹57.23 Cr for FY 2025 (up 57.00% YoY).
The current directors of Lords Mark Biotech Private Limited are:
The primary industry of Lords Mark Biotech Private Limited is healthcare. The company specifically operates in diagnostic centers and pathology labs. The company is currently active in this sector.
Lords Mark Biotech Private Limited can be reached at the registered office: B 101 Ridhi Sidhi Complex M.G Road Borivali East Mumbai, Maharashtra, India – 400066, or through the website lordsmark.com.
The authorised capital is ₹5 Cr, and the paid-up capital is ₹5 Cr.